NCT05217238

Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Yangzhou University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

As a medium-and long-term non-depolarizing muscle relaxant, rocuronium has the advantages of quick effect, no histamine release and accumulation and no obvious cardiovascular adverse reactions, so it has been widely used in clinical anesthesia induction. However, when given intravenously, rocuronium can cause adverse reactions such as injection pain and limb retraction, which can lead to needle prolapse, extravasation of injection drugs, swelling of injection site, serious induction delay, and cardiovascular adverse events in severe cases. Remifentanil is a synthetic opioid drug hydrolyzed by esterase. Compared with other opioid drugs, remifentanil has the advantages of quick effect, short half-life and short time of hemodynamic changes, so it is an ideal analgesic in clinical anesthesia. In this study, in order to provide clinical references, sequential method was used to find the median effective dose (ED50) by means of pre-intravenous injection of Remifentanil to suppress pain in rocuronium injection.

Conditions

• Rocuronium
• Injection Pain

Interventions

Type	Name	Description
DRUG	Remifentanil	Advanced intravenous injection of remifentanil before the rocuronium injection

Timeline

• Start date: 2021-12-18
• Primary completion: 2022-03-30
• Completion: 2022-03-30
• First posted: 2022-02-01
• Last updated: 2022-02-01

Locations

1 site across 1 country: China